Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 1
1972 2
1973 1
1974 1
1976 1
1978 2
1979 1
1980 4
1981 1
1982 3
1983 2
1984 2
1985 4
1986 9
1987 8
1988 2
1989 10
1990 5
1991 6
1992 11
1993 9
1994 7
1995 7
1996 6
1997 6
1998 5
1999 7
2000 3
2001 9
2002 20
2003 27
2004 35
2005 43
2006 55
2007 49
2008 65
2009 61
2010 77
2011 100
2012 99
2013 111
2014 115
2015 95
2016 104
2017 84
2018 82
2019 83
2020 95
2021 118
2022 99
2023 85
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

1,702 results

Results by year

Filters applied: . Clear all
Page 1
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Liu Z, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: wang hm. Nat Med. 2021 Sep;27(9):1536-1543. doi: 10.1038/s41591-021-01444-0. Epub 2021 Aug 2. Nat Med. 2021. PMID: 34341578 Clinical Trial.
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Mai HQ, et al. Among authors: wang hm. JAMA. 2023 Nov 28;330(20):1961-1970. doi: 10.1001/jama.2023.20181. JAMA. 2023. PMID: 38015220 Clinical Trial.
The Impact of Di(2-ethylhexyl)phthalate on Cancer Progression.
Chou CK, Yang YT, Yang HC, Liang SS, Wang TN, Kuo PL, Wang HD, Tsai EM, Chiu CC. Chou CK, et al. Arch Immunol Ther Exp (Warsz). 2018 Jun;66(3):183-197. doi: 10.1007/s00005-017-0494-2. Epub 2017 Dec 5. Arch Immunol Ther Exp (Warsz). 2018. PMID: 29209738 Free article. Review.
UPF1: a potential biomarker in human cancers.
Chen BL, Wang HM, Lin XS, Zeng YM. Chen BL, et al. Among authors: wang hm. Front Biosci (Landmark Ed). 2021 Apr 30;26(5):76-84. doi: 10.52586/4925. Front Biosci (Landmark Ed). 2021. PMID: 34027651 Free article. Review.
Total synthesis of bi-magnolignan.
Lu SY, Wang HM, Feng N, Ma AJ. Lu SY, et al. Among authors: wang hm. RSC Adv. 2023 Mar 16;13(13):8844-8846. doi: 10.1039/d3ra01121f. eCollection 2023 Mar 14. RSC Adv. 2023. PMID: 36936845 Free PMC article.
1,702 results